You have been treated for prostate cancer, either with surgery or radiation therapy, and everything went well. This is a major milestone. But treatment does not mark the end of your medical journey. It opens an equally important period: follow-up care .
The question is simple and essential: what should be monitored after prostate cancer treatment, and for how long?
The answer lies in one word: PSA . But it’s not just about getting a blood test every now and then. You need to understand what you’re looking for, why you’re monitoring it, and what a variation can mean.
- After treatment, regular follow-up is essential.
- PSA testing is becoming an excellent monitoring marker
- A rise in PSA levels may indicate a biological recurrence
- Highly effective examinations, such as PET scans at PSMA, now make it possible to locate this recurrence.
Is post-treatment follow-up really necessary?
Yes, without hesitation.
After successful treatment for prostate cancer, it is crucial to maintain long-term medical follow-up . This follow-up is not simply a matter of “checking things out of principle.” Its purpose is to detect as early as possible any potential recurrence of cancer cells that may have escaped the initial treatment.
The rule given here is clear: the patient must be seen every 6 months for 15 years .
This pace may seem long, but it is perfectly justified. Indeed, a relapse does not necessarily occur quickly. It can appear:
- 6 months into treatment,
- at 1 year old ,
- at 5 years old ,
- even 10 years after the initial treatment.
It is precisely for this reason that serious monitoring should not be interrupted too early.
What does follow-up care after prostate cancer include?
The monitoring is based on two main elements:
- a clinical examination , to ensure that everything is generally alright,
- a PSA test , which is the central tool for monitoring.
PSA is often known as the marker that has been used in cancer screening and diagnosis. But it’s important to distinguish between two situations:
- Before treatment , PSA is an imperfect marker for detecting prostate cancer.
- After treatment , it becomes extremely effective at detecting any possible recurrence of the disease.
This is a fundamental point. PSA is not always a good screening tool, but after treatment, it becomes an excellent monitoring tool.
How to interpret PSA levels after prostate surgery?
After surgery for prostate cancer, that is, after removal of the prostate, the logic is simple.
There is no longer a prostate, therefore there should no longer be a measurable PSA level.
In other words, PSA becomes undetectable in the blood.
In this situation, any reappearance of PSA levels is cause for concern. It may indicate that cancerous prostate cells persist somewhere in the body that were not eliminated by treatment.
How to interpret PSA levels after radiotherapy?
After radiotherapy, the interpretation is slightly different.
Why? Because the prostate is still in place . It was treated, but it wasn’t removed. So it’s normal for the PSA level to remain low .
In this case, the PSA:
- decreases gradually
- then stabilizes at a very low rate .
- often around 0.7 , a little more or a little less.
This stable low point has a name: the nadir .
Once this nadir is reached, the PSA level generally does not fall further. But above all, it must not rise again .
What is a biological relapse?
When a PSA is rebuilt after having been:
- undetectable after surgery , or
- very low and stabilized after radiotherapy
We are talking about biological recurrence .
This expression is important because it does not necessarily mean that a visible tumor has already reformed.
A biological recurrence means something else: there are probably still prostate cancer cells in the body , and these cells are starting to become active again.
At this stage:
- There is not necessarily yet a cancer visible on standard imaging.
- There are not necessarily any symptoms.
- but there is a biological signal that indicates the disease can start again.
That is precisely the whole point of monitoring: to identify this phase very early , before a new tumor has time to develop.
Why detecting a relapse early changes everything
When PSA levels rise again, the goal is not to wait passively. It is necessary to identify the cells responsible for this increase .
This search may concern several areas:
- the site initially treated , that is to say the region where the prostate was located,
- the surrounding fabrics ,
- the lymph nodes ,
- other organs , especially bones .
The idea is simple: if the location of the recurrence is quickly identified, the most appropriate strategy can then be discussed based on:
- of the treatment already received
- of the location of the recurrence,
- of the patient’s overall context.
PET scan at PSMA: the key examination in case of PSA rise
Today, there is a particularly effective test for detecting a biological recurrence of prostate cancer: the PSMA PET scan .
When PSA levels rise after treatment, this test allows for the detection of persistent prostate cancer cells with high precision.
Its role is crucial, because it helps to answer the real clinical question: where is the relapse?
Once the location is identified, the subsequent management can be discussed in a much more relevant way.
In practical terms, what should we remember?
If you have been treated for prostate cancer, the message is very clear:
- Follow-up should not be neglected .
- A check-up every 6 months for 15 years is recommended .
- PSA is the central marker in this monitoring .
- After surgery, PSA levels should be undetectable .
- After radiotherapy, PSA levels decrease and then stabilize at a very low level, called the nadir .
- Any rise in PSA should raise suspicion of a biological recurrence .
- In the event of a recurrence, a PET scan at PSMA is now a reference examination to locate the recurrence .
The key point: even when healed, we continue to monitor
Many men believe that once treatment is complete, the problem is definitively behind them. This is often true clinically, but it never eliminates the need for rigorous follow-up.
You can be treated, feel well, be considered cured, and yet still have to continue monitoring your PSA levels. This isn’t contradictory. It’s simply the best way to ensure a safe future.
Post-treatment PSA testing is not a mere administrative detail or formality. It is a powerful monitoring tool , capable of detecting the presence of residual cancer cells early, before they cause visible disease.
Conclusion
After treatment for prostate cancer, monitoring remains an essential part of care. It relies primarily on regular clinical follow-up and PSA testing .
PSA levels are not interpreted in the same way after surgery and after radiotherapy, but in both cases, an increase should be taken seriously. It may indicate a biochemical recurrence , that is, the persistence of cancer cells that must be identified quickly.
Today, PET scans at PSMA play a major role in locating this recurrence and guiding the subsequent therapeutic strategy.
The right approach, therefore, is to continue monitoring relentlessly, even when everything is going well. This is often how one maintains a decisive advantage over the disease.